Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy

Trial Profile

Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Metreleptin (Primary)
  • Indications Lipodystrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 20 May 2017 Planned End Date changed from 31 Jul 2018 to 31 Jul 2025.
    • 23 Nov 2014 Planned number of patients changed from 15 to 30 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top